SCHEMBL30725399

SCHEMBL30725399

COC(=O)c1[nH]c(Br)c(F)c1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.38
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
NPSR1 Q6W5P4 4/20 0.35
XDH P47989 1/20 0.35
MAPT P10636 3/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35
TUBB4B P68371 1/20 0.35
TUBB3 Q13509 1/20 0.35
TUBB2A Q13885 1/20 0.35
TUBB8 Q3ZCM7 1/20 0.35
TUBA3E Q6PEY2 1/20 0.35
TUBA1A Q71U36 1/20 0.35
TUBA1C Q9BQE3 1/20 0.35
TUBB6 Q9BUF5 1/20 0.35
TUBB2B Q9BVA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27148483 0.81 KDM4C (0.36) KDM4CCCNCCDK8NPSR1XDH
SCHEMBL2919386 0.74 L3MBTL1 (0.42) KDM4CCCNCCDK8NPSR1XDH
SCHEMBL22095713 0.74 TUBB4A (0.51) CCNCCDK8MAPTTUBB4ATUBB
SCHEMBL28535609 0.73 CCNC (0.33) CCNCCDK8TUBB4ATUBBTUBA3C
SCHEMBL24283709 0.72 NPSR1 (0.39) KDM4CCCNCCDK8NPSR1XDH
SCHEMBL24761226 0.69 CYP1A2 (0.42) KDM4CNPSR1KDM4EALDH1A1GAA
SCHEMBL16210782 0.69 KDM4C (0.42) KDM4CCCNCCDK8NPSR1XDH
SCHEMBL29813558 0.69 KDM4E (0.40) CCNCCDK8NPSR1XDHKDM4E
SCHEMBL23147987 0.69 KDM4E (0.40) CCNCCDK8NPSR1XDHKDM4E
SCHEMBL12228580 0.69 MAP2 (0.46) NPSR1MAPTTUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4676931-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BioSplice Therapeutics, Inc. (US) 2026-01-14 EP disclosed
US-20250340575-A1 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS INC (US) 2025-11-06 US disclosed
US-20250206746-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2025-06-26 US disclosed
WO-2025137469-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2025-06-26 WO disclosed
CN-119604506-A 4-Alkoxypyrrolo [2,1-f ] [1,2,4] triazines, preparation and use thereof 拜斯丽治疗有限公司 2025-03-11 CN disclosed
WO-2024211797-A1 PYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-20240002391-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF TENARX, INC. 2024-01-04 US disclosed
WO-2023250156-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF BIOSPLICE THERAPEUTICS, INC. (US) 2023-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340575-A1 4-AMINOPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B KDM4C 2625/4885CCNC 1453/4885CDK8 847/4885
US-20240002391-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B KDM4C 2680/4885CCNC 1299/4885CDK8 1058/4885
US-20250206746-A1 4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK2, DYRK1B KDM4C 2680/4885CCNC 1299/4885CDK8 1058/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.